| Date | Title | Description |
| 02.06.2025 | NextCell Pharma announces outcome of exercise of TO2 and resolves on directed share issues to guarantors | NextCell Pharma announces outcome of exercise of TO2 and resolves on directed share issues to guarantors
Mon, Jun 02, 2025 13:15 CET Report this content
THIS PRESS RELEASE MAY NOT BE RELEASED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTL... |
| 28.05.2025 | NextCell Pharma: A New Dawn in Cell Therapy and Financing | NextCell Pharma AB is making waves in the world of cell therapy. With its recent patent for the MSC Prediction Algorithm, the company is poised to revolutionize treatment for autoimmune diseases. This patent is not just a piece of paper; it... |
| 28.05.2025 | Angela Vollstedt joins NextCell Pharma’s Board of Advisors to Strengthen Scientific and Manufacturing Strategy Ahead of Licensing Discussions | Angela Vollstedt joins NextCell Pharma’s Board of Advisors to Strengthen Scientific and Manufacturing Strategy Ahead of Licensing Discussions
Wed, May 28, 2025 09:50 CET Report this content
NextCell Pharma AB ("NextCell" or "... |
| 28.05.2025 | NextCell Pharma receives additional declarations of intent regarding exercise of TO2 | NextCell Pharma receives additional declarations of intent regarding exercise of TO2
Wed, May 28, 2025 13:03 CET Report this content
THIS PRESS RELEASE MAY NOT BE RELEASED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR INTO THE UNI... |
| 26.05.2025 | NextCell Receives US Patent for MSC Prediction Algorithm | NextCell Receives US Patent for MSC Prediction Algorithm
Mon, May 26, 2025 13:00 CET Report this content
NextCell Pharma AB ("NextCell" or "the Company") is pleased to announce the issuance of a US patent titled “MSC Pre... |
| 23.05.2025 | NextCell Pharma receives declarations of intent, subscription undertakings and top guarantees regarding exercise of TO2 | NextCell Pharma receives declarations of intent, subscription undertakings and top guarantees regarding exercise of TO2
Fri, May 23, 2025 12:30 CET Report this content
THIS PRESS RELEASE MAY NOT BE RELEASED, PUBLISHED OR DISTRIBUTED, DIRECT... |
| 20.05.2025 | Navigating Change: Diamyd Medical's Strategic Moves in 2025 | Diamyd Medical is on the brink of transformation. The company, known for its innovative approach to treating Type 1 Diabetes, is making waves with key appointments and financial adjustments. As it stands at the crossroads of growth, the dec... |
| 20.05.2025 | NextCell announces strategic collaboration with Fujifilm Irvine Scientific | NextCell announces strategic collaboration with Fujifilm Irvine Scientific
Tue, May 20, 2025 09:40 CET Report this content
NextCell Pharma AB’s ("NextCell" or "the Company") has entered into a strategic collaboration wit... |
| 19.05.2025 | Eric Strati Joins NextCell Pharma’s Board of Advisors to Support Commercial Strategy for ProTrans | Eric Strati Joins NextCell Pharma’s Board of Advisors to Support Commercial Strategy for ProTrans
Mon, May 19, 2025 13:00 CET Report this content
NextCell Pharma AB ("NextCell") is pleased to announce the appointment of Eric Strat... |
| 19.05.2025 | Diamyd Medical appoints Niklas Axelsson as CFO | Diamyd Medical appoints Niklas Axelsson as CFO
Mon, May 19, 2025 11:30 CET Report this content
Niklas Axelsson has been appointed CFO of Diamyd Medical. He will assume his position in August and will also join the management team. Niklas Ax... |
| 16.05.2025 | A New Dawn for Type 1 Diabetes: The ProTrans Study and Young Hugo's Journey | In the world of medical innovation, hope often flickers like a candle in the dark. For families grappling with chronic conditions, such as type 1 diabetes, that flicker can become a beacon. Eight-year-old Hugo Wahlbeck embodies this hope. D... |
| 16.05.2025 | The exercise period for NextCell Pharma’s warrants of series TO2 begins today | The exercise period for NextCell Pharma’s warrants of series TO2 begins today
Fri, May 16, 2025 08:00 CET Report this content
THIS PRESS RELEASE MAY NOT BE RELEASED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STA... |
| 15.05.2025 | Eight-Year-Old Hugo – Living with Type 1 Diabetes and Participating in the ProTrans Study | Eight-Year-Old Hugo – Living with Type 1 Diabetes and Participating in the ProTrans Study
Thu, May 15, 2025 13:25 CET Report this content
NextCell Pharma AB ("NextCell") is featured in the Future Healthcare – Focus on Diabetes sup... |
| 07.05.2025 | Study published in Nature Medicine shows promising results in Alzheimer’s disease – supports the development of ProTrans at NextCell | Study published in Nature Medicine shows promising results in Alzheimer’s disease – supports the development of ProTrans at NextCell
Wed, May 07, 2025 14:20 CET Report this content
NextCell Pharma AB (“NextCell” or the “Company”) highlights... |
| 28.04.2025 | BioStock: NextCell’s CEO comments on long-term potential | BioStock: NextCell’s CEO comments on long-term potential
Mon, Apr 28, 2025 15:18 CET Report this content
NextCell Pharma highlights the positive trends seen in the preliminary ProTrans data in adolescents, while underscoring the need to wai... |
| 25.04.2025 | NextCell Pharma publishes its Interim Report 2 2024/2025 | NextCell Pharma publishes its Interim Report 2 2024/2025
Fri, Apr 25, 2025 07:30 CET Report this content
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 2 for the period December 1, 2024 – February 28, 2025. The r... |
| 24.04.2025 | NextCell presents detailed analysis of the administrative report from ProTrans-Young | NextCell presents detailed analysis of the administrative report from ProTrans-Young
Thu, Apr 24, 2025 14:10 CET Report this content
NextCell Pharma AB’s ("NextCell" or "the Company") CSO, Lindsay Davies, has been interv... |
| 23.04.2025 | NextCell Presents Quarterly Report | NextCell Presents Quarterly Report
Wed, Apr 23, 2025 14:15 CET Report this content
NextCell Pharma AB ("NextCell" or the "Company") invites investors, analysts and media to an investor presentation in conjunction with th... |
| 15.04.2025 | NextCell CEO Mathias Svahn explains the latest results from ProTrans-YOUNG and his vision for the way forward | NextCell CEO Mathias Svahn explains the latest results from ProTrans-YOUNG and his vision for the way forward
Tue, Apr 15, 2025 13:00 CET Report this content
NextCell Pharma (“the company” or “NextCell”) has published an interview where the... |
| 09.04.2025 | NextCell Pharma's ProTrans-Young Trial: A Glimpse into the Future of Type 1 Diabetes Treatment | NextCell Pharma is making waves in the world of diabetes treatment. Their ongoing clinical trial, ProTrans-Young, is a beacon of hope for young individuals newly diagnosed with type 1 diabetes. The preliminary one-year results from the olde... |
| 09.04.2025 | NextCell’s CSO elected Vice President Elect for ISCT Europe | NextCell’s CSO elected Vice President Elect for ISCT Europe
Wed, Apr 09, 2025 08:50 CET Report this content
NextCell Pharma AB ("NextCell") announces that Dr Lindsay Davies, Chief Scientific Officer at NextCell Pharma AB, has been... |
| 08.04.2025 | QVance’s co-founder is elected to Vice President Elect for ISCT | QVance’s co-founder is elected to Vice President Elect for ISCT
Tue, Apr 08, 2025 09:30 CET Report this content
QVance AB, Huddinge, Sweden has today announced that its co-founder Dr Lindsay Davies, has been elected by the European membersh... |
| 07.04.2025 | Subgroup Analysis: NextCell Presents Preliminary One-Year Results from the Older Age Group in ProTrans-Young | Subgroup Analysis: NextCell Presents Preliminary One-Year Results from the Older Age Group in ProTrans-Young
Mon, Apr 07, 2025 18:05 CET Report this content
NextCell Pharma today announces preliminary one-year results from the older age gro... |
| 28.03.2025 | NextCell’s CSO Appointed to the Board of ATMP Sweden | NextCell’s CSO Appointed to the Board of ATMP Sweden
Fri, Mar 28, 2025 10:00 CET Report this content
NextCell Pharma AB ("NextCell") proudly announces that the company’s Chief Scientific Officer (CSO), Dr. Lindsay Davies, has been... |
| 19.03.2025 | Recognition for NextCell’s CSO from the International Society of Cell and Gene Therapy | Recognition for NextCell’s CSO from the International Society of Cell and Gene Therapy
Wed, Mar 19, 2025 08:45 CET Report this content
NextCell Pharma AB ("NextCell" or "the Company") announces that its CSO, Lindsay Davi... |
| 13.03.2025 | Results from the Older Age Cohort in the ProTrans-Young Paediatric Study Expected in Aprilv | Results from the Older Age Cohort in the ProTrans-Young Paediatric Study Expected in Aprilv
Thu, Mar 13, 2025 08:45 CET Report this content
NextCell Pharma AB ("NextCell" or "the Company") announces that the last patient... |
| 19.02.2025 | All Patients with Severe Virus-Induced Pneumonia Treated in the ProTrans V Study | All Patients with Severe Virus-Induced Pneumonia Treated in the ProTrans V Study
Wed, Feb 19, 2025 13:00 CET Report this content
NextCell Pharma AB ("NextCell") announced today that all patients in the clinical trial ProTrans V, w... |
| 30.01.2025 | NextCell Pharma publish Interim Report 1 2024/2025 | NextCell Pharma publish Interim Report 1 2024/2025
Thu, Jan 30, 2025 08:30 CET Report this content
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 1 for the period September 1, 2024 – November 30, 2024. The report... |
| 17.12.2024 | Long-term Effects with Repeated ProTrans Treatment After 6 Years | Long-term Effects with Repeated ProTrans Treatment After 6 Years
Tue, Dec 17, 2024 12:50 CET Report this content
NextCell Pharma AB reports new results from the ProTrans-Repeat study, where type 1 diabetes patients have been followed for 5 ... |
| 05.12.2024 | Bulletin from Annual General Meeting of Diamyd Medical AB | Bulletin from Annual General Meeting of Diamyd Medical AB
Thu, Dec 05, 2024 16:45 CET Report this content
The Annual General Meeting of Diamyd Medical AB (publ) was held on December 5, 2024.
The Company's income statement and balance sheet ... |
| 05.12.2024 | NextCell Pharma changes Certified Adviser to Redeye AB | NextCell Pharma changes Certified Adviser to Redeye AB
Thu, Dec 05, 2024 08:45 CET Report this content
NextCell Pharma has entered into an agreement with Redeye AB regarding the service as Certified Adviser. Redeye AB will take over as Cert... |
| 26.11.2024 | QVance and Royale International: A New Era in Cell and Gene Therapy Logistics | In the fast-paced world of biotechnology, partnerships can be the lifeblood of innovation. Recently, QVance, a subsidiary of NextCell Pharma, announced a significant collaboration with Royale International. This partnership aims to revoluti... |
| 25.11.2024 | QVance’s Partnerships Driving Innovation in Advanced Therapies | QVance’s Partnerships Driving Innovation in Advanced Therapies
Mon, Nov 25, 2024 08:45 CET Report this content
NextCell Pharma AB*, parent company of QVance, proudly supports QVance’s newly announced partnership with Royale International. T... |
| 25.11.2024 | QVance Announces Partnership with Royale International to Drive Innovation in End-to-End Cell and Gene Therapy Cold Chain Distribution and Quality Control | QVance Announces Partnership with Royale International to Drive Innovation in End-to-End Cell and Gene Therapy Cold Chain Distribution and Quality Control
Mon, Nov 25, 2024 08:30 CET Report this content
QVance has today announced that it ha... |
| 19.11.2024 | QVance and bioMérieux: A New Era in Nordic Quality Control for Advanced Therapies | In the fast-paced world of biotechnology, partnerships can be the lifeblood of innovation. On November 18, 2024, QVance AB, a Swedish startup, announced a significant partnership with bioMérieux Sweden AB. This collaboration aims to elevate... |
| 18.11.2024 | QVance Announces Partnership | QVance Announces Partnership
Mon, Nov 18, 2024 08:50 CET Report this content
NextCell Pharma AB* comments on its subsidiary QVance’s partnership with bioMérieux Sweden AB, which aims to strengthen quality control analytics for cell and gene... |
| 18.11.2024 | QVance AB Announces Nordic Partnership with bioMérieux | QVance AB Announces Nordic Partnership with bioMérieux
Mon, Nov 18, 2024 08:45 CET Report this content
QVance AB, Huddinge, Sweden has today announced it has entered into a partnership with bioMérieux Sweden AB, aimed at enhancing the quali... |
| 15.11.2024 | Conference on the future of Type 1 Diabetes screening organized as part of the ASSET partnership coordinated by Diamyd Medical | Conference on the future of Type 1 Diabetes screening organized as part of the ASSET partnership coordinated by Diamyd Medical
Fri, Nov 15, 2024 09:55 CET Report this content
As part of the ASSET innovation partnership led by Diamyd Medical... |
| 11.11.2024 | A New Dawn for Type 1 Diabetes: The Promise of Diamyd® and Strategic Partnerships | Type 1 Diabetes (T1D) is a relentless adversary. It attacks the body’s ability to produce insulin, leaving millions in a constant battle for blood sugar control. But hope is on the horizon. Diamyd Medical is pioneering a new approach with i... |
| 08.11.2024 | QVance AB publishes particulates article in collaboration with ISCT | QVance AB publishes particulates article in collaboration with ISCT
Fri, Nov 08, 2024 08:45 CET Report this content
QVance AB, Huddinge, Sweden has today announced its co-founder and CSO at parent company, NextCell Pharma AB, Dr Lindsay Dav... |
| 08.11.2024 | QVance AB Publishes Article on Particulates in Cell and Gene Therapy Products in Collaboration with ISCT | QVance AB Publishes Article on Particulates in Cell and Gene Therapy Products in Collaboration with ISCT
Fri, Nov 08, 2024 13:00 CET Report this content
NextCell Pharma AB* announces that its subsidiary, QVance AB, has published an article ... |
| 06.11.2024 | In-depth analysis showing robust Diamyd[®] treatment effects across clinical trials to be shared at the 2024 IDS Diabetes Congress | In-depth analysis showing robust Diamyd[®] treatment effects across clinical trials to be shared at the 2024 IDS Diabetes Congress
Wed, Nov 06, 2024 08:55 CET Report this content
(IDS) Congress in Bruges, Belgium. The analysis will be prese... |
| 04.11.2024 | NextCell Pharma AB participates in BIO-Europe 2024 and welcomes a visit from Minister Ebba Busch | NextCell Pharma AB participates in BIO-Europe 2024 and welcomes a visit from Minister Ebba Busch
Mon, Nov 04, 2024 08:30 CET Report this content
NextCell Pharma AB* proudly announces its participation in BIO-Europe 2024, one of Europe’s mos... |
| 24.10.2024 | NextCell publishes its Year-End Report 2023/2024 | NextCell publishes its Year-End Report 2023/2024
Thu, Oct 24, 2024 07:30 CET Report this content
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Year-End Report for the period September 1, 2023 – August 31, 2024. The report is a... |
| 14.10.2024 | Diamyd Medical highlights precision medicine approach for Type 1 Diabetes at the scientific conferences ISPAD and IDS | Diamyd Medical highlights precision medicine approach for Type 1 Diabetes at the scientific conferences ISPAD and IDS
Mon, Oct 14, 2024 08:45 CET Report this content
Diamyd Medical will participate in two major conferences in the coming wee... |
| 09.10.2024 | Year-End Report 23/24 | Year-End Report 23/24
Wed, Oct 09, 2024 08:15 CET Report this content
September 2023 – August 2024, Diamyd Medical AB (publ), Fiscal year 2023/2024
Precision Medicine for Autoimmune Diabetes
Aiming for Accelerated Market Approval
Diamyd Med... |
| 08.10.2024 | NextCell Pharma invited to present in Tokyo | NextCell Pharma invited to present in Tokyo
Tue, Oct 08, 2024 08:45 CET Report this content
NextCell Pharma AB's* CEO, Mathias Svahn, has been invited by Business Sweden to the Swedish Embassy in Tokyo, to present the company’s ongoing deve... |
| 04.10.2024 | ProTrans highlighted as a promising treatment for type 1 diabetes in Dagens Medicin | ProTrans highlighted as a promising treatment for type 1 diabetes in Dagens Medicin
Fri, Oct 04, 2024 10:06 CET Report this content
NextCell Pharma AB* is proud that their drug candidate ProTrans has been highlighted in Dagens Medicin’s lat... |
| 01.10.2024 | The first children have been treated in the younger age group of the ProTrans-Young study | The first children have been treated in the younger age group of the ProTrans-Young study
Tue, Oct 01, 2024 08:45 CET Report this content
NextCell Pharma AB ("NextCell" or the "Company", Nasdaq First North Growth Market:... |
| 05.09.2024 | Broader health benefits of ProTrans in treatment of type 1 diabetes | Broader health benefits of ProTrans in treatment of type 1 diabetes
Thu, Sep 05, 2024 08:45 CET Report this content
NextCell Pharma AB ("NextCell" or the "Company", Nasdaq First North Growth Market: NXTCL), has presented... |
| 03.09.2024 | CSO Lindsay Davies Co-Chairs ISCT Europe 2024 Meeting | CSO Lindsay Davies Co-Chairs ISCT Europe 2024 Meeting
Tue, Sep 03, 2024 08:45 CET Report this content
NextCell Pharma AB ("NextCell" or the "Company", Nasdaq First North Growth Market: NXTCL), a leader in advanced cell t... |
| 30.07.2024 | Diamyd Medical Announces Positive Interim Analysis Results for Phase 3 Trial in Type 1 Diabetes | Diamyd Medical Announces Positive Interim Analysis Results for Phase 3 Trial in Type 1 Diabetes
Tue, Jul 30, 2024 20:50 CET Report this content
Diamyd Medical today announced a successful interim analysis (non-futility test) for its ongoing... |
| 25.07.2024 | NextCell publishes its Interim Report 3 2023/2024 | NextCell publishes its Interim Report 3 2023/2024
Thu, Jul 25, 2024 07:30 CET Report this content
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 3 for the period September 1, 2023 – May 31, 2024. The report is av... |
| 03.07.2024 | NextCell carries out a directed issue of units to guarantors in connection with the completed rights issue | NextCell carries out a directed issue of units to guarantors in connection with the completed rights issue
Wed, Jul 03, 2024 23:59 CET Report this content
THIS PRESS RELEASE MAY NOT BE RELEASED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIREC... |
| 17.06.2024 | NextCell’s rights issue oversubscribed | NextCell’s rights issue oversubscribed
Mon, Jun 17, 2024 16:10 CET Report this content
THIS PRESS RELEASE MAY NOT BE RELEASED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN, NEW Z... |
| 12.06.2024 | The paediatric diabetes study gets the green light to treat the age group 7 – 11 years | The paediatric diabetes study gets the green light to treat the age group 7 – 11 years
Wed, Jun 12, 2024 12:30 CET Report this content
NextCell Pharma AB (publ) ("NextCell") announces that the Data Safety Monitoring Board for the ... |
| 11.06.2024 | The Board of Directors and management sign in addition to subscription commitments | The Board of Directors and management sign in addition to subscription commitments
Tue, Jun 11, 2024 13:00 CET Report this content
NextCell Pharma AB (publ) ("NextCell" or the "Company") carries out a rights issue of uni... |
| 10.06.2024 | NextCell publishes supplement to the prospectus regarding the rights issue | NextCell publishes supplement to the prospectus regarding the rights issue
Mon, Jun 10, 2024 17:26 CET Report this content
THIS PRESS RELEASE MAY NOT BE RELEASED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES... |
| 05.06.2024 | Cellaviva becomes an independent company under NextCell Pharma | Cellaviva becomes an independent company under NextCell Pharma
Wed, Jun 05, 2024 08:00 CET Report this content
Cellaviva, the stem cell bank operated by NextCell Pharma AB, has announced its transition to an independent company. This strate... |
| 04.06.2024 | NextCell procures top guarantee in ongoing rights issue | NextCell procures top guarantee in ongoing rights issue
Tue, Jun 04, 2024 22:06 CET Report this content
THIS PRESS RELEASE MAY NOT BE RELEASED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES OF AMERICA, AUSTRA... |
| 31.05.2024 | The subscription period in NextCell’s rights issue commences today | The subscription period in NextCell’s rights issue commences today
Fri, May 31, 2024 08:30 CET Report this content
THIS PRESS RELEASE MAY NOT BE RELEASED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES OF AMER... |
| 30.05.2024 | NextCell publishes prospectus in connection with the rights issue of units of approximately SEK 40.1 million | NextCell publishes prospectus in connection with the rights issue of units of approximately SEK 40.1 million
Thu, May 30, 2024 13:00 CET Report this content
THIS PRESS RELEASE MAY NOT BE RELEASED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIR... |
| 28.05.2024 | Single treatment with ProTrans demonstrates long-term therapeutic effect over 5 years | Single treatment with ProTrans demonstrates long-term therapeutic effect over 5 years
Tue, May 28, 2024 14:15 CET Report this content
NextCell Pharma AB ("NextCell" or the "Company") today announces that patients who wer... |
| 27.05.2024 | Bulletin from the Extraordinary General Meeting of NextCell Pharma AB (publ) | Bulletin from the Extraordinary General Meeting of NextCell Pharma AB (publ)
Mon, May 27, 2024 12:30 CET Report this content
At the Extraordinary General Meeting of NextCell Pharma AB (publ) (“NextCell” or the “company”) on 27 May 2024, the... |
| 25.04.2024 | NextCell publishes its Interim Report 2 2023/2024 | NextCell publishes its Interim Report 2 2023/2024
Thu, Apr 25, 2024 07:30 CET Report this content
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 2 for the period September 1, 2023 – Februari 29, 2024. The report ... |
| 24.04.2024 | The Board of Directors of NextCell resolves on a rights issue of units of approximately SEK 40.1 million, subject to approval by an Extraordinary General Meeting | The Board of Directors of NextCell resolves on a rights issue of units of approximately SEK 40.1 million, subject to approval by an Extraordinary General Meeting
Wed, Apr 24, 2024 18:05 CET Report this content
THIS PRESS RELEASE MAY NOT BE ... |
| 24.04.2024 | Notice of Extraordinary General Meeting in NextCell Pharma AB (publ) | Notice of Extraordinary General Meeting in NextCell Pharma AB (publ)
Wed, Apr 24, 2024 18:15 CET Report this content
The shareholders of NextCell Pharma AB (publ), Reg. No. 556965-8361 (”NextCell” or the ”company”), are hereby summoned to a... |
| 22.04.2024 | NextCell’s daughter company Cellaviva granted permission to handle amniotic tissue | NextCell’s daughter company Cellaviva granted permission to handle amniotic tissue
Mon, Apr 22, 2024 14:00 CET Report this content
NextCell Pharma AB ("NextCell" or the "Company") today announces that the Swedish Health ... |
| 19.04.2024 | Anders Essen-Möller resigns as Chairman of the Board of Directors due to health reasons | Anders Essen-Möller resigns as Chairman of the Board of Directors due to health reasons
Fri, Apr 19, 2024 07:30 CET Report this content
NextCell Pharma AB ("NextCell" or the "Company") today announces that its long-time ... |
| 12.04.2024 | Recruitment milestone reached in Diamyd® Phase 3 trial | Recruitment milestone reached in Diamyd® Phase 3 trial
Fri, Apr 12, 2024 09:30 CET Report this content
Diamyd Medical’s precision medicine Phase 3 trial for Type 1 Diabetes, DIAGNODE-3, has enrolled 100 patients. To date, no serious adverse... |
| 27.03.2024 | The Swedish Medical Products Agency approves subgroup analysis in NextCell's ProTrans-Young study | The Swedish Medical Products Agency approves subgroup analysis in NextCell's ProTrans-Young study
Wed, Mar 27, 2024 10:20 CET Report this content
NextCell Pharma AB ("NextCell" or the "Company") today announces that the ... |
| 14.03.2024 | NextCell establishes QVance to meet the Nordic’s need for quality analytics | NextCell establishes QVance to meet the Nordic’s need for quality analytics
Thu, Mar 14, 2024 08:45 CET Report this content
NextCell Pharma AB ("NextCell" or the "Company") today announces that it has formed a subsidiary... |
| 27.02.2024 | NextCell Pharma’s updated growth strategy | NextCell Pharma’s updated growth strategy
Tue, Feb 27, 2024 08:45 CET Report this content
NextCell Pharma AB ("NextCell" or the "Company") today announces that the Company has decided to implement strategic changes. The ... |
| 14.02.2024 | NextCell Pharma presents at Redeye Theme: Regenerative Medicine/Cell Therapy | NextCell Pharma presents at Redeye Theme: Regenerative Medicine/Cell Therapy
Wed, Feb 14, 2024 09:15 CET Report this content
Today Wednesday on February 14th at 10.30 CET Dr. Mathias Svahn, CEO of NextCell Pharma AB (“NextCell" or the&... |
| 25.01.2024 | NextCell publishes its Interim Report 1 2023/2024 | NextCell publishes its Interim Report 1 2023/2024
Thu, Jan 25, 2024 07:30 CET Report this content
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 1 for the period September 1, 2023 – November 30, 2023. The report ... |
| 24.01.2024 | Updates regarding NextCell’s Clinical Trials with ProTrans | Updates regarding NextCell’s Clinical Trials with ProTrans
Wed, Jan 24, 2024 13:00 CET Report this content
NextCell Pharma has several ongoing clinical trials with ProTrans. The largest ongoing study ProTrans Young, which includes 66 patien... |
| 13.12.2023 | NextCell Pharma has compiled a Q&A section | NextCell Pharma has compiled a Q&A section
Wed, Dec 13, 2023 13:00 CET Report this content
NextCell Pharma AB ("NextCell" or the "Company") has compiled questions from the company’s stakeholders in a Q&A section.... |
| 06.11.2023 | Repeated treatment with ProTrans is immunologically safe | Repeated treatment with ProTrans is immunologically safe
Mon, Nov 06, 2023 13:00 CET Report this content
NextCell Pharma AB ("NextCell" or the "Company") today announces that multiple treatments with ProTrans cell therap... |
| 26.10.2023 | NextCell publishes its Year-End Report 2022/2023 | NextCell publishes its Year-End Report 2022/2023
Thu, Oct 26, 2023 07:30 CET Report this content
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Year-End Report for the period September 1, 2022 – August 31, 2023. The report is a... |
| 10.10.2023 | NextCell signs an agreement for a new tissue product | NextCell signs an agreement for a new tissue product
Tue, Oct 10, 2023 13:00 CET Report this content
NextCell Pharma AB (“NextCell” or “the company”) announces that the company has signed an agreement with the Finnish biotechnology company ... |
| 05.09.2023 | NextCell Pharma presents at the Advanced Therapies Europe conference | NextCell Pharma presents at the Advanced Therapies Europe conference
Tue, Sep 05, 2023 09:00 CET Report this content
NextCell Pharma participates in Advanced Therapies Europe, a European conference in Portugal on advanced cell therapies. Ne... |
| 08.08.2023 | ProTrans and NextCell gain international attention | ProTrans and NextCell gain international attention
Tue, Aug 08, 2023 08:45 CET Report this content
Results from Professor Per-Ola Carlsson, Principal Investigator for NextCell’s Phase-I/II study with ProTrans stromal cells for Type 1 Diabet... |
| 27.07.2023 | NextCell publishes its Interim Report 3 2022/2023 | NextCell publishes its Interim Report 3 2022/2023
Thu, Jul 27, 2023 07:30 CET Report this content
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 3 for the period March 1, 2023 – May 31, 2023 The report is availab... |
| 05.07.2023 | Treatment start of severe pneumonia with high dose of ProTrans | Treatment start of severe pneumonia with high dose of ProTrans
Wed, Jul 05, 2023 08:45 CET Report this content
NextCell Pharma AB ("NextCell" or the "Company") announces that the clinical trial ProTrans 19+SE (also calle... |
| 30.05.2023 | NextCell invited presenter at International Society for Cell and Gene Therapy meeting in Paris | NextCell invited presenter at International Society for Cell and Gene Therapy meeting in Paris
Tue, May 30, 2023 10:00 CET Report this content
NextCell Pharma AB´s ("NextCell" or the"Company") CSO, Dr Lindsay Davies, has... |
| 27.04.2023 | NextCell publishes its Interim Report 2 2022/2023 | NextCell publishes its Interim Report 2 2022/2023
Thu, Apr 27, 2023 07:30 CET Report this content
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 2 for the period December 1, 2022 – February 28, 2023 The report is... |
| 26.04.2023 | Breakthrough multiplication of blood stem cells | Breakthrough multiplication of blood stem cells
Wed, Apr 26, 2023 08:50 CET Report this content
NextCell Pharma AB (“NextCell” or the “company") announces that the FDA has approved a product of multiplied stem cells from umbilical cord... |
| 18.04.2023 | NextCell invited speaker at European Wound Management Association Meeting in Milan | NextCell invited speaker at European Wound Management Association Meeting in Milan
Tue, Apr 18, 2023 10:00 CET Report this content
NextCell Pharma AB´s ("NextCell" or the "Company") CSO, Dr Lindsay Davies, has been invit... |
| 28.03.2023 | NextCell´s publication of the phase I/II clinical trial in type I diabetes accepted | NextCell´s publication of the phase I/II clinical trial in type I diabetes accepted
Tue, Mar 28, 2023 08:55 CET Report this content
NextCell Pharma AB (”NextCell” or ”Company”) have had their article detailing the results of their phase I/I... |
| 21.03.2023 | NextCell’s CSO elected to ISCT European Regional Secretary | NextCell’s CSO elected to ISCT European Regional Secretary
Tue, Mar 21, 2023 13:00 CET Report this content
NextCell Pharma AB’s ("NextCell" or the "Company") CSO, Lindsay Davies, has been officially elected to the positi... |
| 07.03.2023 | NextCell’s CSO nominated for ISCT European Regional Secretary | NextCell’s CSO nominated for ISCT European Regional Secretary
Tue, Mar 07, 2023 14:30 CET Report this content
NextCell Pharma AB’s ("NextCell" or the "Company") CSO, Lindsay Davies, has been nominated for the position of... |
| 26.01.2023 | NextCell publishes its Interim Report 1 2022/2023 | NextCell publishes its Interim Report 1 2022/2023
Thu, Jan 26, 2023 07:30 CET Report this content
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 1 for the period September 1, 2022 – November 30, 2022 The report i... |
| 18.01.2023 | Positive feedback on the paediatric plan of the EMA | Positive feedback on the paediatric plan of the EMA
Wed, Jan 18, 2023 13:00 CET Report this content
NextCell Pharma AB ("NextCell") has received positive comments and recommendations for the pediatric investigational plan (PIP) su... |
| 21.12.2022 | First pediatric patients treated with ProTrans in type-1 diabetes phase II study | First pediatric patients treated with ProTrans in type-1 diabetes phase II study
Wed, Dec 21, 2022 13:00 CET Report this content
NextCell Pharma AB ("NextCell") supports the pediatric diabetes clinical trial conducted at Uppsala U... |
| 28.10.2022 | Pediatric diabetes trial with ProTrans gets green light for phase II part | Pediatric diabetes trial with ProTrans gets green light for phase II part
Fri, Oct 28, 2022 11:10 CET Report this content
NextCell Pharma AB ("NextCell") announces that the Data Safety Monitoring Board has recommended professor Pe... |
| 27.10.2022 | Resend / NextCell publishes its Year-End Report 2021/2022 | Resend / NextCell publishes its Year-End Report 2021/2022
Thu, Oct 27, 2022 11:32 CET Report this content
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Year-End Report for the period September 1, 2021 – August 31, 2022 The rep... |
| 27.10.2022 | NextCell publishes its Year-End Report 2021/2022 | NextCell publishes its Year-End Report 2021/2022
Thu, Oct 27, 2022 07:30 CET Report this content
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Year-End Report for the period September 1, 2021 – August 31, 2022 The report is av... |
| 27.10.2022 | NextCell presentation of Interim analysis data today at 15:00 | NextCell presentation of Interim analysis data today at 15:00
Thu, Oct 27, 2022 13:00 CET Report this content
NextCell Pharma AB ("NextCell" or the "Company") has developed a proprietary and patented platform technology ... |
| 25.08.2022 | ProTrans cell therapy to be granted patent protection beyond Europe | ProTrans cell therapy to be granted patent protection beyond Europe
Thu, Aug 25, 2022 13:15 CET Report this content
NextCell Pharma AB ("NextCell" or the "Company") today announces that the Japan Patent Office (JPO) has ... |
| 28.07.2022 | NextCell Pharma publishes Interim Report 3 2021/2022 | NextCell Pharma publishes Interim Report 3 2021/2022
Thu, Jul 28, 2022 07:30 CET Report this content
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 3 for the period September 1, 2021 – May 31, 2022 The report is ... |